0	11	Cyclosporin	Cyclosporin	NNP
12	13	A	A	NNP
14	22	inhibits	inhibit	VBZ
23	28	early	early	JJ
29	33	mRNA	mrna	NN
34	44	expression	expression	NN
45	47	of	of	IN
48	53	G0/G1	g0/g1	NN
54	60	switch	switch	NN
61	65	gene	gene	NN
66	67	2	2	CD
68	69	(	(	(
69	73	G0S2	g0s2	NN
73	74	)	)	)
75	77	in	in	IN
78	86	cultured	culture	VBN
87	92	human	human	JJ
93	98	blood	blood	NN
99	110	mononuclear	mononuclear	JJ
111	116	cells	cell	NNS
116	117	.	.	.

119	130	Cyclosporin	Cyclosporin	NNP
131	132	A	A	NNP
133	134	(	(	(
134	137	CsA	CsA	NNP
137	138	)	)	)
139	142	may	may	MD
143	150	achieve	achieve	VB
151	154	its	its	PRP$
155	172	immunosuppressive	immunosuppressive	JJ
173	180	effects	effect	NNS
181	183	by	by	IN
184	194	inhibiting	inhibit	VBG
195	198	the	the	DT
199	207	calcium-	calcium-	NN
208	211	and	and	CC
212	232	calmodulin-dependent	calmodulin-dependent	JJ
233	244	phosphatase	phosphatase	NN
245	256	calcineurin	calcineurin	NN
257	262	which	which	WDT
263	265	is	be	VBZ
266	274	required	require	VBN
275	278	for	for	IN
279	289	activation	activation	NN
290	292	of	of	IN
293	299	target	target	NN
300	305	genes	gene	NNS
306	308	by	by	IN
309	316	members	member	NNS
317	319	of	of	IN
320	323	the	the	DT
324	328	NFAT	NFAT	NNP
329	330	(	(	(
330	337	nuclear	nuclear	JJ
338	344	factor	factor	NN
345	347	of	of	IN
348	357	activated	activate	VBN
358	359	T	t	NN
360	365	cells	cell	NNS
365	366	)	)	)
367	380	transcription	transcription	NN
381	387	factor	factor	NN
388	394	family	family	NN
394	395	.	.	.

396	401	Among	among	IN
402	407	these	these	DT
408	414	target	target	NN
415	420	genes	gene	NNS
421	423	is	be	VBZ
424	427	the	the	DT
428	432	gene	gene	NN
433	441	encoding	encode	VBG
442	455	interleukin-2	interleukin-2	NN
456	457	(	(	(
457	460	IL2	IL2	NNP
460	461	)	)	)
461	462	,	,	,
463	464	a	a	DT
465	473	cytokine	cytokine	NN
474	486	facilitating	facilitate	VBG
487	498	progression	progression	NN
499	506	through	through	IN
507	510	the	the	DT
511	513	G1	g1	NN
514	519	phase	phase	NN
520	522	of	of	IN
523	526	the	the	DT
527	531	cell	cell	NN
532	537	cycle	cycle	NN
537	538	.	.	.

539	546	However	however	RB
546	547	,	,	,
548	551	IL2	IL2	NNP
552	556	does	do	VBZ
557	560	not	not	RB
561	568	reverse	reverse	VB
569	572	CsA	CsA	NNP
573	583	inhibition	inhibition	NN
583	584	,	,	,
585	595	suggesting	suggest	VBG
596	600	that	that	IN
601	603	at	at	IN
604	609	least	least	JJS
610	613	one	one	CD
614	619	other	other	JJ
620	634	NFAT-sensitive	nfat-sensitive	JJ
635	639	gene	gene	NN
640	643	may	may	MD
644	646	be	be	VB
647	655	involved	involve	VBN
655	656	.	.	.

657	660	The	the	DT
661	666	human	human	JJ
667	672	G0/G1	g0/g1	NN
673	679	switch	switch	NN
680	684	gene	gene	NN
684	685	,	,	,
686	690	G0S2	G0S2	NNP
690	691	,	,	,
692	695	has	have	VBZ
696	705	potential	potential	JJ
706	718	NFAT-binding	nfat-binding	JJ
719	724	sites	site	NNS
725	727	in	in	IN
728	731	the	the	DT
732	733	5	5	CD
733	734	’	'	SYM
735	740	flank	flank	NN
741	744	and	and	CC
745	752	encodes	encode	VBZ
753	754	a	a	DT
755	760	small	small	JJ
761	766	basic	basic	JJ
767	776	potential	potential	JJ
777	791	phosphoprotein	phosphoprotein	NN
792	794	of	of	IN
795	802	unknown	unknown	JJ
803	811	function	function	NN
811	812	.	.	.

813	818	Using	use	VBG
819	820	a	a	DT
821	830	sensitive	sensitive	JJ
830	831	,	,	,
832	839	reverse	reverse	JJ
840	864	transcription-polymerase	transcription-polymerase	NN
865	870	chain	chain	NN
871	879	reaction	reaction	NN
880	881	(	(	(
881	887	RT-PCR	RT-PCR	NNP
887	888	)	)	)
889	894	assay	assay	NN
894	895	,	,	,
896	900	G0S2	g0s2	NN
901	905	mRNA	mrna	NN
906	912	levels	level	NNS
913	917	were	be	VBD
918	925	assayed	assay	VBN
926	928	in	in	IN
929	937	cultured	culture	VBN
938	943	blood	blood	NN
944	955	mononuclear	mononuclear	JJ
956	961	cells	cell	NNS
961	962	.	.	.

963	970	Freshly	freshly	RB
971	979	isolated	isolate	VBN
980	985	cells	cell	NNS
986	993	contain	contain	VBP
994	998	high	high	JJ
999	1005	levels	level	NNS
1006	1008	of	of	IN
1009	1013	G0S2	g0s2	NN
1014	1018	mRNA	mRNA	NNP
1019	1024	which	which	WDT
1025	1032	rapidly	rapidly	RB
1033	1040	decline	decline	VBP
1040	1041	.	.	.

1042	1046	This	this	DT
1047	1048	“	``	``
1048	1059	spontaneous	spontaneous	JJ
1060	1071	stimulation	stimulation	NN
1071	1072	”	''	''
1073	1075	is	be	VBZ
1076	1080	also	also	RB
1081	1086	noted	note	VBN
1087	1091	with	with	IN
1092	1096	some	some	DT
1097	1102	other	other	JJ
1103	1106	G0S	G0S	NNP
1107	1112	genes	gene	NNS
1113	1116	and	and	CC
1117	1120	has	have	VBZ
1121	1125	been	be	VBN
1126	1136	attributed	attribute	VBN
1137	1139	to	to	TO
1140	1144	some	some	DT
1145	1151	aspect	aspect	NN
1152	1154	of	of	IN
1155	1158	the	the	DT
1159	1168	isolation	isolation	NN
1169	1178	procedure	procedure	NN
1178	1179	.	.	.

1180	1182	In	in	IN
1183	1188	cells	cell	NNS
1189	1193	that	that	WDT
1194	1198	have	have	VBP
1199	1203	been	be	VBN
1204	1216	preincubated	preincubate	VBN
1217	1219	to	to	TO
1220	1225	lower	lower	VB
1226	1230	mRNA	mrna	NN
1231	1237	levels	level	NNS
1237	1238	,	,	,
1239	1244	there	there	EX
1245	1247	is	be	VBZ
1248	1249	a	a	DT
1250	1259	transient	transient	JJ
1260	1268	increase	increase	NN
1269	1271	in	in	IN
1272	1276	G0S2	G0S2	NNP
1277	1281	mRNA	mRNA	NNP
1281	1282	,	,	,
1283	1290	peaking	peak	VBG
1291	1298	between	between	IN
1299	1302	1-2	1-2	CD
1303	1304	h	h	NN
1304	1305	,	,	,
1306	1308	in	in	IN
1309	1317	response	response	NN
1318	1320	to	to	TO
1321	1335	Concanavalin-A	Concanavalin-A	NNP
1336	1337	(	(	(
1337	1341	ConA	ConA	NNP
1341	1342	)	)	)
1342	1343	,	,	,
1344	1346	or	or	CC
1347	1349	to	to	TO
1350	1353	the	the	DT
1354	1365	combination	combination	NN
1366	1368	of	of	IN
1369	1376	phorbol	phorbol	NN
1377	1382	ester	ester	NN
1383	1384	(	(	(
1384	1387	TPA	TPA	NNP
1387	1388	)	)	)
1388	1389	,	,	,
1390	1393	and	and	CC
1394	1397	the	the	DT
1398	1405	calcium	calcium	NN
1406	1415	ionophore	ionophore	NN
1415	1416	,	,	,
1417	1426	ionomycin	ionomycin	NN
1426	1427	.	.	.

1428	1432	Both	both	DT
1433	1438	these	these	DT
1439	1448	responses	response	NNS
1449	1452	are	be	VBP
1453	1462	inhibited	inhibit	VBN
1463	1465	by	by	IN
1466	1469	CsA	CsA	NNP
1469	1470	.	.	.

1471	1474	Our	our	PRP$
1475	1482	results	result	NNS
1483	1490	suggest	suggest	VBP
1491	1495	that	that	IN
1496	1500	G0S2	g0s2	NN
1501	1511	expression	expression	NN
1512	1514	is	be	VBZ
1515	1523	required	require	VBN
1524	1526	to	to	TO
1527	1533	commit	commit	VB
1534	1539	cells	cell	NNS
1540	1542	to	to	TO
1543	1548	enter	enter	VB
1549	1552	the	the	DT
1553	1555	G1	g1	NN
1556	1561	phase	phase	NN
1562	1564	of	of	IN
1565	1568	the	the	DT
1569	1573	cell	cell	NN
1574	1579	cycle	cycle	NN
1579	1580	,	,	,
1581	1584	and	and	CC
1585	1589	that	that	IN
1589	1590	,	,	,
1591	1596	while	while	IN
1597	1600	not	not	RB
1601	1610	excluding	exclude	VBG
1611	1616	other	other	JJ
1617	1625	possible	possible	JJ
1626	1633	targets	target	NNS
1633	1634	,	,	,
1635	1640	early	early	JJ
1641	1651	inhibition	inhibition	NN
1652	1654	of	of	IN
1655	1659	G0S2	g0s2	NN
1660	1670	expression	expression	NN
1671	1673	by	by	IN
1674	1677	CsA	CsA	NNP
1678	1681	may	may	MD
1682	1684	be	be	VB
1685	1694	important	important	JJ
1695	1697	in	in	IN
1698	1707	achieving	achieve	VBG
1708	1725	immunosuppression	immunosuppression	NN
1725	1726	.	.	.

1727	1731	G0S2	G0S2	NNP
1732	1735	may	may	MD
1736	1738	be	be	VB
1739	1741	of	of	IN
1742	1747	value	value	NN
1748	1750	as	as	IN
1751	1752	a	a	DT
1753	1761	reporter	reporter	NN
1762	1766	gene	gene	NN
1767	1770	for	for	IN
1771	1780	analyzing	analyze	VBG
1781	1784	the	the	DT
1785	1794	mechanism	mechanism	NN
1795	1797	of	of	IN
1798	1804	action	action	NN
1805	1807	of	of	IN
1808	1811	CsA	CsA	NNP
1812	1815	and	and	CC
1816	1819	its	its	PRP$
1820	1829	influence	influence	NN
1830	1832	on	on	IN
1833	1836	the	the	DT
1837	1845	positive	positive	JJ
1846	1849	and	and	CC
1850	1858	negative	negative	JJ
1859	1868	selection	selection	NN
1869	1871	of	of	IN
1872	1883	lymphocytes	lymphocyte	NNS
1884	1886	in	in	IN
1887	1895	response	response	NN
1896	1898	to	to	TO
1899	1903	self	self	NN
1904	1907	and	and	CC
1908	1916	not-self	not-self	JJ
1917	1925	antigens	antigen	NNS
1925	1926	.	.	.